Numerically comparable reductions were seen for central aortic systolic pressure ( CASP ) in aliskiren-based therapy ( baseline : 143.715.0 ; week 36 : -20.316.2 ) compared with ramipril-based therapy ( baseline : 147.911.9 ; week 36 : -20.714.6 ) .